Subscribe To
Target ceo on consumer spending: 'they're buying less stuff'
Target CEO Brian Cornell weighed in on spending behavior that the retailer has observed among its custo...
November 3, 2023, 4:21 pm
Sbf's verdict marks the end of a crypto era
In an outcome that won’t surprise observers, Sam Bankman-Fried, the Founder and former CEO of collaps...
November 3, 2023, 4:08 pm
These are the small-caps to consider
Small-caps have been a frustrating asset class this year, and that sentiment extends beyond U.S. borders. With ample frequency, market ...
November 1, 2023, 9:20 am
Kanda announces japan is on “standby” as yen plunges past 151 to dollar
Amid the resumed selloff of Yen, which broke 151 level against Dollar overnight, Japan’s top currency official, Masato Kanda, has issued a stern ver...
November 1, 2023, 2:55 am
Wolfspeed stock soars on record q1 revenue, growth
Shares of American chipmaker Wolfspeed (WOLF) are skyrocketing Tuesday morning after reporting fiscal first-quarter earnings for 2024, citing four per...
October 31, 2023, 10:11 am
Xrp’s race to the $1: a deep dive into its potential climb!
XRP’s Race to the $1: A Deep Dive into Its Potential Climb! XRP, with its roller coaster of challenges and victories, is back in the limelight, posi...
October 31, 2023, 8:38 am
Have bad loans become a problem for us banks?
The health of the banking industry is an important indicator of overall economic health. There has recently been increased worry regarding the presenc...
October 30, 2023, 2:33 pm
Ubs says its way too early to begin talking about european central bank interest rate cuts
UBS describe the rate decision from the ECB meeting on Thursday as a non-event. Highlights from the note:the remarks following emphasised again the do...
October 26, 2023, 11:49 pm
Gold demand at record levels in 2023, beating crypto by nearly 50% - lbma ceo crowell
(Kitco News) - Unprecedented levels of gold demand have been observed in 2023 with central banks purcha...
October 26, 2023, 4:16 pm
Gold price forecast: xau/usd confirms bull flag, re-attempts $2,000
As observed on the daily chart, Gold price confirmed a Bull Flag formation after closing Wednesday abov...
October 26, 2023, 4:14 am
Australia cpi slows to 5.4% yoy in q3, but rises to 5.6% yoy in sep
Australia’s CPI for Q3 registered a 1.2% qoq rise, exceeding expectation of 1.1% qoq and marking an acceleration from the previous quarter’s 0.8% ...
October 25, 2023, 1:18 am
A wild few minutes drive bitcoin above $35,000 as etf excitement starts to thaw the crypto winter
It was exciting enough for crypto observers when bitcoin [BTC] topped $31,000 on Monday.And then its pr...
October 24, 2023, 7:29 am
Shiba inu rides bitcoin’s $34k wave, shib burn rate rockets 600% amid market frenzy
Shiba Inu (CRYPTO: SHIB), a meme coin, has observed a 6% increase in the last 24 hours, as a wider mark...
October 24, 2023, 5:14 am
Infrastructure matters for future ev adoption
This year, there's no shortage of EV market observers noting that an inflection point for the industry ...
October 23, 2023, 12:32 pm
Bitcoin eyes $31k as gold offers bullish cues
Interest rate-sensitive assets, such as Gold, are seeing bullish momentum in a positive sign for bitcoin, one ...
October 23, 2023, 5:29 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metast...
October 22, 2023, 10:01 am